gle

Oglemilast (GRC 3886) suppresses pulmonary cell infiltration, including eosinophilia and neutrophilia in vitro and in vivo. Oglemilast is an effective and orally active phosphodiesterase-4 (PDE4) inhibitor (IC50: 0.5 nM for PDE4D3). Oglemilast has the potential for inflammatory airway diseases.

Englerin A, a TRPC4 and TRPC5 channel agonist, is a compound from the East African plant Phyllanthus engleri with analgesic, anti-inflammatory, and anticancer activities that induces necrosis in human renal cancer cells.

Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.

Gleditsiasaponin C' is a useful organic compound for research related to life sciences and the catalog number is T124251.

Gleditsioside J is a useful organic compound for research related to life sciences. The catalog number is T125199 and the CAS number is 253123-52-3.

Gleditsioside A is a useful organic compound for research related to life sciences. The catalog number is T125267 and the CAS number is 230302-68-8.

Gleditsioside 1 is a useful organic compound for research related to life sciences. The catalog number is T125270 and the CAS number is 229468-56-8.

Gleditsioside G is a useful organic compound for research related to life sciences. The catalog number is T125292 and the CAS number is 225529-55-5.

Gleditsioside E is a useful organic compound for research related to life sciences. The catalog number is T125293 and the CAS number is 225529-54-4.

Gleditsioside F is a useful organic compound for research related to life sciences. The catalog number is T125294 and the CAS number is 225524-86-7.

(-)-Englerin B is a natural product that can be used as a reference standard.

Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.

Glesatinib is an orally active and potent dual inhibitor of MET SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.

Kanglexin is an orally active novel anthraquinone compound. It inhibits NLRP3 inflammasome activation and pyroptosis, offering cardioprotective benefits. By stimulating the FGFR1 ERK signaling pathway, Kanglexin promotes angiogenesis and accelerates wound healing in diabetes. Additionally, it has lipid-lowering effects and inhibits vascular smooth muscle cell dedifferentiation, making it a potential compound for studying hyperlipidemia, fatty liver, and atherosclerosis.

Aglepristone is a synthetic steroidal antiprogestogen related to mifepristone and possesses some antiglucocorticoid activity. It is specifically used as an abortifacient in pregnant animals.

Glemanserin (MDL11939) is a specific 5-HT2A antagonist with Ki values of 0.54 nM, 2.5 nM and 2.89 nM for rabbit, human and rat 5-HT2A.

1. Negletein (7-O-Methylbaicalein) has anti-inflammatory and immunomodulatory activities via inhibition of TNF-α, iNOS and IL-1β. 2. Negletein as a neuroprotectant enhances the action of nerve growth factor and induces neurite outgrowth in PC12 cells. 3. Negletein shows a comparable redox-active potential, and it (50 μM, 4 h) can activate Nrf2. 4. Negletein shows significant antimicrobial activity. 5. Negletein has anti-hypoxia activity, it can significantly prolong the survival time of hypoxic mice.6. Negletein has anti- Alzheimer's disease activity, it inhibits the iron-dependent formation of ROS and also blocks the iron-induced oligomerization of amyloid beta 42 in vitro. 7. Negletein (IC50: 3.89 + - 0.39 microM) exhibits potent inhibitory activity against nuclear factor of activated T cells (NFAT) transcription factor.

The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the SARS-CoV-2 RBD. [1]

Telaglenastat (CB-839) hydrochloride is a first-in-class, reversible, and orally active inhibitor of glutaminase 1 (GLS1), selectively inhibiting the splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C), as opposed to GLS2. Telaglenastat hydrochloride has an IC50 of 23 nM for endogenous glutaminase in mouse kidney and 28 nM in the brain, inducing autophagy and exhibiting antitumor activity.

Glecaprevir (ABT-493) is an HCV NS3 4A protease inhibitor, (IC50s: 3.5-11.3 nM).

Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.

Efpeglenatide is a long-acting agonist of the glucagon-like peptide (GLP-1) receptor. efpeglenatide improves insulin sensitivity and slows weight loss in mice models of diabetes and obesity. efpeglenatide has been used in studies of type II diabetes.

Glenvastatin is a HMG-CoA reductase inhibitor which has a pyridine-based structure.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).